The COVID-19 pandemic saw one of the fastest developments of vaccines in an effort to combat an out-of-control pandemic. The 2 most common COVID-19 vaccine platforms currently in use, messenger RNA (mRNA) and adenovirus vector, were developed on the basis of previous research in use of this technology…
The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to the rapid development of highly effective vaccines, which have proven to be the most important tool in combating the coronavirus disease 2019 (COVID-19) pandemic. Initial clinical trials reported no major adverse events beyond rare cases of anaphylaxis…
In soggetti recentemente sottoposti a vaccinazione anti-SARS-CoV-2 con i vaccini a vettore virale Vaxzevria (ChAdOx1 nCov-19 della ditta Astra Zeneca) e con COVID-19 Vaccine Janssen (Ad.26.COV2.S della ditta Johnson & Johnson) sono state riportate diverse segnalazioni di eventi trombotici in sedi atipiche (trombosi dei seni venosi cerebrali e/o del distretto splancnico), associati a piastrinopenia e con decorsi clinici di particolare gravità…
Coronavirus disease 2019 (COVID-19) has been associated with an increased incidence of thrombotic events, including stroke. However, characteristics and outcomes of COVID-19 patients with stroke are not well known…
Cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare and serious condition, has been described in Europe following receipt of the ChAdOx1 nCoV-19 vaccine (Oxford/AstraZeneca), which uses a chimpanzee adenoviral vector. A mechanism similar to autoimmune heparin-induced thrombocytopenia (HIT) has been proposed…
Patients with coronavirus disease 2019 (Covid-19) may experience venous thrombosis while data regarding arterial thrombosis are sparse. Prospective multicenter study in 5 hospitals including 373 patients with Covid-19-related pneumonia…
The manifestations of COVID-19 as outlined by imaging modalities such as echocardiography, lung ultrasound (LUS), and cardiac magnetic resonance (CMR) imaging are not fully described. We conducted a systematic review of the current literature and included studies that described cardiovascular manifestations of COVID-19 using echocardiography, CMR, and pulmonary manifestations using LUS…
Coronavirus disease 19 (COVID-19) has become a global threat. Its clinical course is different from other common illnesses and mortality remains high…
Stroke may complicate coronavirus disease 2019 (COVID-19) infection based on clinical hypercoagulability. We investigated whether transcranial Doppler ultrasound has utility for identifying microemboli and clinically relevant cerebral blood flow velocities (CBFVs) in COVID-19…
Bedside lung ultrasound (LUS) can play a role in the setting of the SarsCoV2 pneumonia pandemic. To evaluate the clinical and LUS features of COVID-19 in the ED and their potential prognostic role, a cohort of laboratory-confirmed COVID-19 patients underwent LUS upon admission in the ED…
Relatore: Margit Battisti Matscher
Relatore: Cornelia Scerra
Relatore: Nicolò G.M. Bevilacqua
Relatore: Emanuela Buda
Relatore: Daniele Peric
Carissime/i,
il terzo ed ultimo Incontro di Aggiornamento per l’anno 2021, si è tenuto giovedì 7 Ottobre ed ha riguardato “L’ Ecografia Intestinale” durante il quale, grazie alla qualità dei relatori intervenuti, è stato possibile fare un’eccellente puntualizzazione sullo stato attuale dell’ecografia nell’ambito delle malattie intestinali.
Carissime/i,
Il secondo Incontro di Aggiornamento, attivato con il format Live Webinar, è stato “L’ECD dei tronchi Sovraortici ” e si e’ tenuto giovedì 6 Maggio su piattaforma e-learning. L’evento rientra nel percorso formativo intitolato “Incontri di Aggiornamento in Ecografia” che, per il 2021, si terrà integralmente in digitale e prevede 3 Incontri…
Carissime/i, la situazione contingente legata alla pandemia Covid-19, venendo a mancare le condizioni indispensabili per la realizzazione degli eventi in presenza, ci ha indotto ad optare per la realizzazione di eventi in digitale.
As observed in other infections with a systemic inflammatory response, severe COVID-19 is associated with hypercoagulability and a prothrombotic state. Currently, there is growing evidence that pulmonary embolism and thrombosis contribute to adverse outcomes and increased mortality in critically ill patients with COVID-19…
The SARS-CoV-2 infection (COVID-19) is causing an ongoing pandemic and potentially fatal disease. Development of coagulopathy with thrombotic complications such as deep vein thrombosis and pulmonary embolism are emerging as factors for progression to severe disease and death. Also, a markedly increased level of D-dimer, a protein product of fibrin degradation, has been associated to mortality…
